Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232779 | 0.88 | GAA (0.62) | GAAKMT2AL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL2234416 | 0.85 | GAA (0.59) | GAAKMT2AL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL2233791 | 0.85 | GAA (0.60) | GAAKMT2AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL10893778 | 0.84 | KMT2A (0.72) | GAAKMT2AL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL28948322 | 0.82 | GAA (0.54) | GAAKMT2AL3MBTL1MAPTKDM4E | |
| SCHEMBL29163015 | 0.82 | GAA (0.65) | GAAKMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20984472 | 0.80 | GAA (0.71) | GAAKMT2AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL11622540 | 0.79 | GAA (0.61) | GAAKMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL15568571 | 0.78 | GAA (0.60) | GAAKMT2AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL28315327 | 0.78 | GAA (0.61) | GAASMN1; SMN2MAPTLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299264-B2 | Method for producing oxadiazolinone compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2357167-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | AHR, CYP1B1, AR | GAA 4157/4885KMT2A 1740/4885L3MBTL1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.